Evolution of remission as the new standard in the treatment of depression

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 22, 1999, Pages 7-11

  Nierenberg, Andrew A ^a   Wright, Emma C ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR; CLOMIPRAMINE; CYCLOHEXANOL DERIVATIVE; DRUG DERIVATIVE; MIANSERIN; MIRTAZAPINE; VENLAFAXINE; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; SERTRALINE; UNCLASSIFIED DRUG;

ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; DEPRESSION; DISTRESS SYNDROME; DYSTHYMIA; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; REMISSION; FEMALE; HOSPITALIZATION; MALE; PREVALENCE; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; REVIEW; STATISTICS; TREATMENT OUTCOME; HIGH RISK PATIENT; RECURRENCE RISK; SYMPTOM; WELLBEING;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS; CLOMIPRAMINE; CYCLOHEXANOLS; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIANSERIN; PREVALENCE; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0033378990     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Clinical Practice Guideline Number 5: Depression in Primary Care, vol 2: Treatment of Major Depression. Rockville, Md; US Dept Health Human Services, Agency for Health Care Policy and Research; 1993. AHCPR publication 93-0551
2. Hooper MB, Amsterdam JD. Do clinical trials reflect drug potential? a review of 5 FDA evaluations of new antidepressants [poster 182). Presented at the 38th annual meeting of the New Clinical Drug Evaluation Unit Program (NCDEU) of the National Institute of Mental Health; June 10-13, 1998; Boca Raton, Fla
3. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
4. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48:851-855
5. Judd LL, Akiskal HS, Paulus MP. The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depressive disorder. J Affect Disord 1997;45:5-18
6. Horwath E, Johnson J, Klerman GL, et al. Depressive symptoms as relative and attributable risk factors for first-onset major depression. Arch Gen Psychiatry 1992;49:817-823
7. Maier W, Gansicke M, Weiffenbach O. The relationship between major and subthreshold variants of unipolar depression. J Affect Disord 1997;45: 41-51
8. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998;50:97-108
9. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999; 60:221-225
10. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995;25: 1171-1180
11. Van Londen L, Molenaar RP, Goekoop JG, et al. Three-to 5-year prospective follow-up of outcome in major depression. Psychol Med 1998;28: 731-735
12. Rush AJ, Trivedi MH. Treating depression to remission. Psychiatr Ann 1995;25:704-705, 709
13. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
14. Kramer PD. Listening to Prozac. New York, NY: Viking; 1993
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
16. Kessler RC, Zhao S, Blazer DG, et al. Prevalence, correlates, and course of minor depression and major depression in the National Comorbidity Survey. J Affect Disord 1997;45:19-30
17. Johnson J, Weissman MM, Klerman GL. Service utilization and social morbidity associated with depressive symptoms in the community. JAMA 1992;267:1478-1483
18. Rapaport MH, Judd LL. Minor depressive disorder and subsyndromal depressive symptoms: functional impairment and response to treatment. J Affect Disord 1998;48:227-232
19. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
20. Thase ME, Sullivan LR. Relapse and recurrence of depression: a practical approach for prevention. CNS Drugs 1995;4:261-277
21. Faravelli C, Ambonetti A, Pallanti S, et al. Depressive relapses and incomplete recovery from index episode. Am J Psychiatry 1986;143:888-891
22. Simons AD, Murphy GE, Levine JL, et al. Cognitive therapy and pharmacotherapy for depression: sustained improvement over one year. Arch Gen Psychiatry 1986;43:43-48
23. Evans MD, Hollon SD, DeRubeis RJ, et al. Differential relapse following cognitive therapy and pharmacotherapy for depression. Arch Gen Psychiatry 1992;49:802-808
24. Lin EHB, Katon WJ, VonKorff M, et al. Relapse of depression in primary care: rate and clinical predictors. Arch Fam Med 1998;7:443-449
25. Mintz J, Mintz LI, Arruda MJ, et al. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 1992;49:761-768
26. Angst J, Delinistula A, Stabl M, et al. Is a cutoff score a suitable measure of treatment outcome in short-term trials in depression: a methodological meta-analysis. Hum Psychopharmacol Clin Exp 1993;8:311-317
27. Keller MB, Gelenberg AJ, Hirschfeld RMA, et al. The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. J Clin Psychiatry 1998;59:598-607
28. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-299
29. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine, a controlled multicenter study. Psychopharmacology (Berl) 1986;90:131-138
30. Clere GE, Ruimy P, Verdeau-Pailles J, et al. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Irt Clin Psychopharmacol 1994;9:139-143
31. Guslfi JD, White C, Hackett D, et al. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 1995;56:450-458
32. Wheatley DP, van Moffaert M, Timmerman L, et al, and the Mirtazapine-Fluoxetine Study Group. Mirtazapine: efficacy and tolerability in comparisor with fluoxetine in patients with moderate to severe depressive disorder. J Clin Psychiatry 1998;59:306-312
33. Stahl SM. Are two antidepressant mechanisms better than one? [BRAINSTORMS] J Clin Psychiatry 1997;58:339-340
34. Khan A, Upton GV, Rudolph RL, et al. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. J Clin Psychopharmacol 1998;18:19-25
35. Fava GA, Grandi S, Zielezny M, et al. Cognitive behavioral treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry 1994;151:1295-1299
36. Fava GA, Rafanelli C, Grandi S, et al. Prevention of recurrent depression with cognitive behavioral therapy: preliminary findings. Arch Gen Psychiatry 1998;55:816-820
37. Fava GA, Rafanelli C, Grandi S, et al. Six-year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry 1998;155:1443-1445